ResearcherBeijing Chao-Yang Hospital, Capital Medical UniversityActive in the last 2 years

Ran Xue

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3978-6066; OpenAlex author ID A5069341396. Sources: OpenAlex.

Their work

Papers: 4 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 2 papers

Papers 4

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yawei Liu · 1 shared paper, 2025 · strength 0.54
- Paper Pancreatic stellate cell: Update on molecular investigations and clinical translation in pancreatic cancer. DOI 10.1002/ijc.35326 ↗
Jun Zhou · 1 shared paper, 2025 · strength 0.24
- Paper A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitab… DOI 10.1038/s41392-025-02530-2 ↗
Zhi-Hua Li · 1 shared paper, 2025 · strength 0.24
- Paper A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitab… DOI 10.1038/s41392-025-02530-2 ↗
Miaoyan Wei · 1 shared paper, 2025 · strength 0.24
- Paper A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitab… DOI 10.1038/s41392-025-02530-2 ↗
Lin Shen · 1 shared paper, 2025 · strength 0.24
- Paper A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitab… DOI 10.1038/s41392-025-02530-2 ↗
Xianjun Yu · 1 shared paper, 2025 · strength 0.24
- Paper A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitab… DOI 10.1038/s41392-025-02530-2 ↗
Yuhong Zhou · 1 shared paper, 2025 · strength 0.24
- Paper A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitab… DOI 10.1038/s41392-025-02530-2 ↗
Jianyu Hao · 2 shared papers, 2018 · strength 0.19
- Paper Mitofusin2 Induces Cell Autophagy of Pancreatic Cancer through Inhibiting the PI3K/Akt/mTOR Signaling Pathway. DOI 10.1155/2018/2798070 ↗
- Paper Derivation and Validation of the Potential Core Genes in Pancreatic Cancer for Tumor-Stroma Crosstalk. DOI 10.1155/2018/4283673 ↗
Di Lu · 1 shared paper, 2018 · strength 0.10
- Paper Mitofusin2 Induces Cell Autophagy of Pancreatic Cancer through Inhibiting the PI3K/Akt/mTOR Signaling Pathway. DOI 10.1155/2018/2798070 ↗
Yanbin Wang · 1 shared paper, 2018 · strength 0.10
- Paper Mitofusin2 Induces Cell Autophagy of Pancreatic Cancer through Inhibiting the PI3K/Akt/mTOR Signaling Pathway. DOI 10.1155/2018/2798070 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.